Impact of long COVID on diverse Australian populations: a multi-site, longitudinal prospective cohort study protocol Authors: Shiqi Luo, Zhen Zheng, Leila Karimi, Magdalena Plebanski, Kate Louise McCann Anderson, Natalie Jovanovski, Chintha Lankatillake, Wendell Cockshaw, Dennis Wollersheim, Jacob Sheahan, Emma-Louise Seal, Kerryn Butler-Henderson, Donald Campbell, April Clarke, Sonja Cleary, Jessica Danaher, Doa El-Ansary, Bernardo Figueiredo, Katie L Flanagan, Claire Hines, Rebecca L Jessup, Hanife Mehmet, Suzanne M Miller, Marie-Claire Seeley, Manoj Sivan, Franca Smarrelli, Adam B Smith, Gillian Vesty, Dein Vindigni, Sophia Xenos, Louisa Stocco, Samantha Hartman, Ilan Ivory, Catherine Itsiopoulos Published: 2026 ABSTRACT AbstractBackgroundLong COVID is a complex, multisystem chronic condition that may persist or fluctuate for months to years after SARS-CoV-2 infection. Despite emerging international research, significant gaps remain in understanding the full breadth of long COVID’s impacts in Australia. No study has yet prospectively examined these multidimensional impacts using a culturally appropriate, user-validated toolkit. Our study aims to characterise symptom profiles, functional outcomes and psychological, social, financial and behavioural impacts of long COVID in Australian adults; identify factors associated with recovery trajectories; and validate a set of measures to support research and clinical care.MethodsThis national, multi-site, longitudinal prospective cohort study comprises three phases: (1) survey selection and user-testing; (2) psychometric validation; and (3) a longitudinal cohort study. Survey selection was informed by literature review, Australian parliament inquiry reports and international recommendations, and refined through iterative user-testing and expert review. A total of 1000 participants aged ≥18 years from diverse cultural backgrounds with ongoing symptoms following COVID-19 infection will be divided into three cohorts based on time since infection. Surveys will be administered at seven time points over 24 months, with optional follow-up to 36 months. Data linkage to state and national health datasets will enable an objective assessment of healthcare utilisation and associated costs. Psychometric properties of the tools will be evaluated using baseline responses from the initial 300 participants, including assessments of structural/construct validity, convergent validity, known-groups validity, cross-validity, internal reliability, responsiveness and test–retest reliability. Other data analyses will include descriptive statistics, repeated-measures analysis of variance, linear mixed-effects modelling and multivariable regression models.Ethics and disseminationEthics approval was obtained from The St Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) (112108/2024/PID00364) and RMIT University HREC (28124). Research findings will be disseminated at conferences and in peer-reviewed publications.Trial registration numberAustralian New Zealand Clinical Trials Registry (ACTRN12625001415493). STRENGTHS AND LIMITATIONS OF THIS STUDY The survey was developed using a triangulated approach combining qualitative user-testing, consumer engagement, expert review and quantitative methods. The survey was developed using a triangulated approach combining qualitative user-testing, consumer engagement, expert review and quantitative methods. The longitudinal design allows repeated measurement of symptoms, functioning and broader impacts over time. The longitudinal design allows repeated measurement of symptoms, functioning and broader impacts over time. The study involves researchers, clinicians, nurses, allied health professionals and people with lived experience, supporting interdisciplinary input into the study design. The study involves researchers, clinicians, nurses, allied health professionals and people with lived experience, supporting interdisciplinary input into the study design. Potential limitations include selection bias, attrition and missing data. Potential limitations include selection bias, attrition and missing data. Reliance on self-reported data and under-representation of severely affected individuals may limit completeness and accuracy. Reliance on self-reported data and under-representation of severely affected individuals may limit completeness and accuracy. Introduction Background Long COVID, also called post-acute sequelae of COVID-19, is a post-infection chronic condition that affects multiple organ systems.1 The WHO defines it as either persistent symptoms or the new onset of symptoms, 3 months after the initial SARS-CoV-2 infection, with symptoms lasting for at least 2 months and having no other identifiable cause.2 There are over 200 symptoms associated with long COVID which often appear in clusters, frequently overlap and can fluctuate over time.3 While global attention has shifted beyond the acute pandemic response, an estimated 65 million people continue to experience ongoing challenges associated with long COVID4 that impact quality of life and health outcomes. Long COVID is life-changing, particularly for the subset experiencing dysautonomia, a disruption to the autonomic nervous system and/or severe fatigue that resembles myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).5 6 Globally, there is a paucity of longitudinal studies on long COVID.7 Within these limited studies, survey studies predominantly follow participants for short periods of time, usually for up to 1 year.8 A number of studies have examined the impact of long COVID on quality of life (QoL) and functional performance9; however, only one study to date has specifically examined its financial impact on individuals.10 These longitudinal survey-based studies have significantly contributed to our understanding of long COVID and its progression. For instance, while many people with long COVID recover within 12 months, approximately 8%–18% continue to experience symptoms beyond 2 years.11 12 Despite this emerging evidence, a significant gap remains in our understanding of how long COVID impacts other important aspects of life, such as relationships, career trajectories, social participation and community roles. Long COVID may affect every domain of a person’s life, including physical, functional, psychological, social, behavioural and financial, extending beyond general health or QoL concerns.1317 Our preliminary research identified that both social support and individual self-efficacy can influence recovery and health outcomes.18 The broad impact of long COVID among the Australian population is also reflected in the recent parliamentary inquiry report Sick and Tired: Casting a Long Shadow, which received over 500 submissions from individuals and organisations providing support to people with long COVID.19 Together, these findings highlight that the impacts of long COVID extend beyond individual health to broader social, occupational and economic consequences, placing a substantial burden on both the healthcare system and the national economy.19 To date, no Australian study has systematically and prospectively examined the full breadth of long COVID’s impacts, which represents a critical evidence gap. Advancing long COVID care requires a standardised toolkit of valid, reliable and culturally sensitive measures to capture these multidimensional impacts across diverse populations and track changes over time. Without robust longitudinal data, there is a limited understanding of recovery trajectories, the factors that shape individual outcomes and how impacts evolve across physical, psychological, social and economic domains. Aims Primary aim Of this project is to characterise the symptoms, functional profiles and overall impact of long COVID on Australian adults from diverse populations, including culturally and linguistically diverse (CALD) groups, First Peoples, (We use the term First Peoples throughout this article, as recommended by our First Peoples researcher, to refer to Aboriginal and Torres Strait Islander peoples, the original custodians of the lands and waters now called Australia. This term recognises their enduring sovereignty, diverse cultures and deep connections to Country.) older adults, people with disabilities and individuals experiencing social disadvantage. Physical, psychological, functional, social, financial and behavioural impacts will be monitored every 3–6 months over a 36-month period, capturing changes across different stages of the condition. The secondary aims are to: Select, refine and validate reliable tools for measuring the impact of long COVID, with active input from people who have lived or living experience of the condition. Select, refine and validate reliable tools for measuring the impact of long COVID, with active input from people who have lived or living experience of the condition. Identify key factors that influence individuals’ experiences and recovery trajectories. Identify key factors that influence individuals’ experiences and recovery trajectories. Findings from this research will generate a detailed, longitudinal understanding of the impacts of long COVID across diverse Australian populations, as well as the factors shaping individual experiences and recovery trajectories. This work is expected to also contribute to the development of a comprehensive assessment toolkit to inform clinical practice, health service delivery, research and the evaluation of costs associated with interventions and healthcare service innovations for long COVID. This project has three phases, including phase 1: survey selection, user-testing and expert review for content validity, phase 2: psychometric validation and phase 3: longitudinal prospective cohort study. Phase 1 was completed prior to the survey launch in December 2025 and phases 2 and 3 are currently in progress. Methods Study design This is a national, multi-site, longitudinal prospective cohort study. The design of the study is informed by the International Severe Acute Respiratory and emerging Infection Consortium COVID-19 follow-up protocol.20 The reporting of the study will follow the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines21 and Sex and Gender Equity in Research (SAGER) guidelines.22 Study setting This study will be conducted across three research sites: RMIT University and Northern Health, both based in Victoria, Australia; and Hands on Health Australia (HoHA), a national not-for-profit community organisation. RMIT University brings an interdisciplinary research team, supported by well-established connections to national long COVID clinician networks and online peer support communities, including the long COVID Facebook group. Northern Health, primarily the Victorian Virtual Emergency Department (VVED), provides access to a large and diverse cohort of individuals affected by COVID-19 and long COVID. HoHA brings a strong track record of working with disadvantaged and low socioeconomic communities, including people experiencing homelessness, and provides consultation on developing a culturally safe approach to involving First Peoples. Participant recruitment will be nationwide, using professional networks, social media and hospital and HoHA databases. Data will be collected using online, telephone and in-person methods. Participants will be surveyed over a 36-month period, with surveys administered at baseline and at regular intervals (every 3–6 months). Study period The longitudinal prospective cohort study is expected to run from December 2025 to December 2029. Phase 1 survey selection, user-testing and expert review for content validity Survey selection process The selection of outcome measure tools is informed by published UK and Australian studies23 and the core outcome measures recommended by international experts.24 In addition, a comprehensive literature review was conducted to identify impacts, risks and predictive factors of long COVID, and commonly used outcome measurement tools. The focus was on tools that assess the impacts of long COVID, with preference given to those that have been validated for the Australian population and/or are suitable for longitudinal studies. Among these, the modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) was identified as a comprehensive measure capturing the severity of key persistent symptoms, functional limitations, additional symptoms and overall health status in individuals with long COVID.23 It aligns closely with the domains of the WHO’s International Classification of Functioning, Disability and Health (ICF) framework, which provides a holistic perspective on functioning and disability and facilitates a more nuanced understanding of overall health.23 We also mapped impacts identified from the Australian Commonwealth Government’s 2023 report Sick and Tired: Casting a Long Shadow,19 against the domains covered in the selected tools. Where gaps were identified, we developed additional questions to address them, resulting in 10 custom questions created by the research team. Candidate measures selected are shown in table 1. Table 1Selected measurement toolsNamePurposeNumber of items and time to completeRefC19-YRSmEvaluate the common symptoms, functional disability, overall health, social role, impact on employment in long COVID. This tool has been validated in a UK-based cohort of individuals with long COVID (n=1314)17 items12 min 23 60 EQ-5D-5LMeasure the impacts on health-related quality of life of people with long COVID. This is a widely used and validated tool globally. It has also been validated among Australians with chronic conditions such as multiple sclerosis (n=1683) and within the Aboriginal Australian population (n=1012)6 items3 min 25 61 62 MAPSIdentify the potential subtype of long COVID POTS. The tool has been validated in a Swedish cohort with POTS (n=69)12 items6 min 26 F-SozU K-3Social Support ScaleAssess perceived social support. This tool has been validated in a representative sample of the general German population (n=2501)3 items2 min 27 UCLA Loneliness Scale (LS) 3Assess relational connectedness, social connectedness and self-perceived isolation. It has been widely used and validated in multiple languages, including among general populations in Croatia (n=309) and Greece (n=223), and Chinese individuals with a diagnosis of schizophrenia (n=300)3 items2 min 2863 65 FACIT-FatigueAssess self-reported fatigue and its impact on daily activities and function. It has been validated internationally across populations with various chronic conditions, including people with Crohn’s disease in the USA (n=1065) and individuals undergoing maintenance dialysis in China (n=172)13 items7 min 30 66 67 Mini-EATAssess diet quality and identify nutritional factors that may support long COVID recovery. It has been validated in US adults (n=661), including patients from a preventive cardiology clinic, those in cardiac rehabilitation and healthy volunteers14 items7 min 31 IPAQ-SFEvaluate the impact of long COVID on physical activity levels. This tool has been widely used and validated internationally, including in a Dutch population with chronic fatigue syndrome (n=226) and in the general Australian population (n=177)7 items4 min 33 68 SSCI-8Measure enacted and internalised stigma. It is validated in US adults (n=587) with neurological disorders8 items4 min 34 Selected measurement tools included (1) the modified C19-YRSm; (2) EQ-5D-5L; (3) MAPS; (4) F-SozU K-3 Social Support Scale; (5) UCLA Loneliness Scale 3; (6) the FACIT-Fatigue; (7) the Mini-EAT; (8) the IPAQ-SF and (9) the adapted SSCI-8.C19-YRSm, COVID-19 Yorkshire Rehabilitation Scale; EQ-5D-5L, EuroQol 5-Dimension 5-Level questionnaire; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue Scale; IPAQ-SF, International Physical Activity Questionnaire-Short Form; MAPS, MALMO Postural Orthostatic Tachycardia Syndrome (POTS) Score; Mini-EAT, Mini-Eating Assessment Tool; SSCI-8, Stigma Scale for Chronic Illnesses 8-item version. Selected measurement tools Selected measurement tools included (1) the modified C19-YRSm; (2) EQ-5D-5L; (3) MAPS; (4) F-SozU K-3 Social Support Scale; (5) UCLA Loneliness Scale 3; (6) the FACIT-Fatigue; (7) the Mini-EAT; (8) the IPAQ-SF and (9) the adapted SSCI-8. C19-YRSm, COVID-19 Yorkshire Rehabilitation Scale; EQ-5D-5L, EuroQol 5-Dimension 5-Level questionnaire; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue Scale; IPAQ-SF, International Physical Activity Questionnaire-Short Form; MAPS, MALMO Postural Orthostatic Tachycardia Syndrome (POTS) Score; Mini-EAT, Mini-Eating Assessment Tool; SSCI-8, Stigma Scale for Chronic Illnesses 8-item version. The C19-YRSm tool quantifies the severity of key persistent symptoms, functional disabilities, other symptoms and overall health in individuals with long COVID.23 The C19-YRSm tool quantifies the severity of key persistent symptoms, functional disabilities, other symptoms and overall health in individuals with long COVID.23 The EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) is a validated, concise tool designed to assess five key dimensions of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, as well as overall health. It is sensitive to change and widely used in health research.25 However, psychometric data for this tool in Australians with long COVID are currently lacking. The EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) is a validated, concise tool designed to assess five key dimensions of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, as well as overall health. It is sensitive to change and widely used in health research.25 However, psychometric data for this tool in Australians with long COVID are currently lacking. MALMO Postural Orthostatic Tachycardia Syndrome (POTS) Score (MAPS) survey is a tool co-designed with consumers, and it includes an optimal cut-off value to discriminate between POTS and healthy controls.26 It has been reported that more than three-quarters of people with long COVID experience POTS.26 MALMO Postural Orthostatic Tachycardia Syndrome (POTS) Score (MAPS) survey is a tool co-designed with consumers, and it includes an optimal cut-off value to discriminate between POTS and healthy controls.26 It has been reported that more than three-quarters of people with long COVID experience POTS.26 F-SozU K-3 (Social Support Scale) is a valid and reliable screening tool to measure perceived social support.27 F-SozU K-3 (Social Support Scale) is a valid and reliable screening tool to measure perceived social support.27 UCLA LS-3 is a validated and reliable instrument measuring three dimensions of loneliness, including relational connectedness, social connectedness and self-perceived isolation.28 It has been used to evaluate loneliness among older adults in Australia.29 UCLA LS-3 is a validated and reliable instrument measuring three dimensions of loneliness, including relational connectedness, social connectedness and self-perceived isolation.28 It has been used to evaluate loneliness among older adults in Australia.29 The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) is a validated patient-reported outcome tool used to assess fatigue-related symptoms and their effects on daily functioning.30 The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) is a validated patient-reported outcome tool used to assess fatigue-related symptoms and their effects on daily functioning.30 The Mini-Eating Assessment Tool is a validated, brief dietary screener that efficiently assesses diet quality by focusing on key food groups essential for positive health outcomes. It could help identify nutritional factors that support long COVID recovery and provide actionable guidance on dietary changes to reduce symptom severity and improve overall health.31 32 The Mini-Eating Assessment Tool is a validated, brief dietary screener that efficiently assesses diet quality by focusing on key food groups essential for positive health outcomes. It could help identify nutritional factors that support long COVID recovery and provide actionable guidance on dietary changes to reduce symptom severity and improve overall health.31 32 The International Physical Activity Questionnaire-Short Form is designed for the assessment of physical activity through seven questions on frequency, duration and intensity.33 It is used to assess the impact of long COVID on physical activity levels.33 The International Physical Activity Questionnaire-Short Form is designed for the assessment of physical activity through seven questions on frequency, duration and intensity.33 It is used to assess the impact of long COVID on physical activity levels.33 The adapted Stigma Scale for Chronic Illnesses 8-item version (SSCI-8) is a validated instrument that captures both internalised perceptions of stigma and external experiences of discrimination in chronic illness.34 For people with long COVID and other invisible chronic illnesses involving fatigue and energy limitation, stigma is frequently reported and adds to the overall burden of the condition.35 It remains a persistent barrier to health and well-being, influencing health-seeking behaviour and clinical outcomes, and may have substantial effects on population health.34 35 The adapted Stigma Scale for Chronic Illnesses 8-item version (SSCI-8) is a validated instrument that captures both internalised perceptions of stigma and external experiences of discrimination in chronic illness.34 For people with long COVID and other invisible chronic illnesses involving fatigue and energy limitation, stigma is frequently reported and adds to the overall burden of the condition.35 It remains a persistent barrier to health and well-being, influencing health-seeking behaviour and clinical outcomes, and may have substantial effects on population health.34 35 Patient and public involvement Our research decisions for the study design are guided by individuals with firsthand experience of long COVID or similar conditions such as ME/CFS, who form a Lived Experience Advisory Network (LEAN) for our broader project. Four LEAN members, who also have advocacy or leadership experience in the chronic illness community, provided feedback on survey scope, comprehensibility and accessibility. Additional consultations with community leaders from key intersectional groups, such as First Peoples and women with disability, ensured the survey’s cultural sensitivity and relevance. The survey underwent multiple revisions based on this feedback. Three LEAN members reviewed and commented on the proposed modes of recruitment and data collection, including the anticipated time required to complete the surveys and the perceived burden of participation. LEAN members will continue to be involved in later phases of the study, including reviewing summaries of findings and contributing to dissemination plans for wider long COVID communities. User-testing User-testing is an essential component of the early-validation protocols for research materials such as survey instruments, ensuring that the material is suitable for the target population. The aim of this activity was to identify and remediate common usability issues known to affect survey accuracy, including item wording, question interpretation, accessibility, recall and cognitive or emotional workload.36 37 Draft versions of the survey were tested in two rounds with 14 adults living with long COVID (nine women, four men, and one nonbinary person, located across four Australian states). Four testers identified as LGBTQIA+. The age of testers ranged from 36 to 67 years, and testers had lived with long COVID for 19 months to 4 years. User testers were recruited through flyers posted to the Australian long COVID Facebook group, with the criteria that individuals have a diagnosis of (self or via health professional) long COVID. Engaging user testers as a representative sample of the target population allowed us to identify and address ambiguities, misunderstandings and biases inherent in our research materials. Iterative user testing combined concurrent and retrospective cognitive interview techniques, alongside qualitative observations of user behaviour.36 37 Using a concurrent Think Aloud approach, participants first completed the survey while verbalising their cognitive and affective responses to items in real-time, with minimal prompts like ‘can you tell me what you’re thinking?’ used when necessary.38 Occasionally, deeper verbal prompts were used to unpack a response, for example, ‘how did you calculate that figure?’ or ‘what are you including in that response?’. At the end of each session, retrospective cognitive interviews were used to review participants’ responses and experiences in greater depth, guided by Neilsen’s Usability Heuristics39 and the Cognitive Aspects of Survey Methodology model.40 Following testing, several major changes were made to the survey, notably: (1) rewording or removal of unclear and irrelevant items, (2) clarifications and reminders for recall periods and severity ratings, (3) reordering item sequence, (4) adding regular pacing reminders and (5) adding justifications, skip options and conditional, trauma-informed support messaging for potentially sensitive items. Detailed findings from this process will be discussed in a forthcoming publication. Expert review-content validity Content validity ensures that the items in a measurement tool adequately reflect the concept it is intended to assess.41 To confirm the survey toolkit captures the full scope of the impacts of long COVID, we engaged a panel of seven Australian healthcare professionals experienced in long COVID care, together with three health interpreters working in Greek, Arabic and Mandarin communities. Experts were invited to review the draft survey via individual or group interviews, conducted online. They assessed the clarity, relevance and cultural appropriateness of each item and provided suggestions for refinement or additional content where needed. Interviews were recorded with consent, and responses were coded prior to analysis. Experts were recruited through professional networks to reflect a diversity of perspectives, including those from clinical, allied health, and priority population backgrounds. Findings from the expert review informed the iterative refinement of the survey, including adding new measures (eg, SSCI-8), developing new items (eg, smoking, vaping and alcohol-related questions) and refining item wording and response options to improve cultural appropriateness. Phase 2 psychometric validation and phase 3 longitudinal prospective cohort study Participants We will include participants who (1) are 18 years old and above; (2) living in Australia with plans to remain for at least the next 2 years, and with no restriction on ethnic or cultural background or English proficiency; and (3) meet criteria aligned with the WHO definition for long COVID,2 including a history of COVID-19 infection, confirmed with a PCR or rapid antigen test positive or being a close contact of a confirmed case and developing COVID-19-like symptoms themselves at the same time, with ongoing symptoms that cannot be explained by an alternative diagnosis. This approach allows inclusion of suspected cases in recognition of the variability of testing access and practices, particularly during the early phases of the pandemic and in the post-pandemic period where testing is no longer routinely undertaken. We will exclude those who are (1) critically ill (≥1 vital-organ failure and high risk of imminent death)42 and currently requiring intensive care; and (2) individuals unable to autonomously provide informed consent. We will reach out to a diverse group of potential participants and stratify them post-recruitment into three cohorts based on the time since COVID-19 infection: Cohort 1 (subacute group): individuals who are between 1 and 3 months post-infection and are still experiencing symptoms will be allocated to the subacute group. Cohort 1 (subacute group): individuals who are between 1 and 3 months post-infection and are still experiencing symptoms will be allocated to the subacute group. Cohort 2 (long COVID group): individuals who are between 3 and 12 months post-infection with ongoing symptoms will be allocated to the long COVID group. Cohort 2 (long COVID group): individuals who are between 3 and 12 months post-infection with ongoing symptoms will be allocated to the long COVID group. Cohort 3 (persistent long COVID group): individuals who are over 12 months post-infection and continue to experience symptoms will be allocated to the persistent long COVID group for further follow-up. Cohort 3 (persistent long COVID group): individuals who are over 12 months post-infection and continue to experience symptoms will be allocated to the persistent long COVID group for further follow-up. The three cohorts represent distinct phases of the post-COVID-19 trajectory. In particular, the distinction between cohorts 2 (3–12 months) and 3 (>12 months) reflects entry within, as compared with beyond, the commonly used recovery window, allowing examination of factors associated with longer-term symptom and recovery trajectories. Sample size With an expected medium to large effect size, a power of 0.80, and a significance level of 0.05, a total of 680 participants is required for multilevel, multi-design analysis. Considering an attrition rate of 40% due to the longitudinal nature of the study,43 44 a minimum of 1000 participants is recommended. We will target the recruitment of 330 participants in cohort 1 (subacute group), 335 participants in cohort 2 (long COVID group) and 335 participants in cohort 3 (persistent long COVID group). Sampling strategy We plan to recruit a diverse group of people using different strategies described in the following paragraphs. Recruitment will follow three stages, starting with the general population with a subsequent focus on high-priority groups. Recruitment will be conducted through three study sites: RMIT University, Northern Health (primarily through VVED) and HoHA. Stage 1 We will begin by reaching out to individuals who self-identify as confident with completing the survey in English, before targeting people from all ethnic and cultural backgrounds. Given the selected study sites, this stage will ensure that the research can encompass individuals representing the breadth of Australian society, including those from marginalised groups such as older adults (people aged 65 years and over), people with lower socioeconomic status (SES) and members of the LGBTQIA+ community. Stage 2 Next, we will engage individuals from CALD backgrounds who might have more limited English proficiency. This will include communities that experienced higher COVID-19 infection rates and/or speakers of the most common languages spoken at home in Australia other than English, such as Mandarin, Arabic and Greek.45 46 Target groups will also include South Pacific Islanders and older adults from aged care facilities. Stage 3 Finally, we will focus on recruiting First Peoples (First Peoples continue to experience significant health inequities in Australia, driven by the ongoing impacts of colonisation, systemic racism and unequal access to care. Ensuring the inclusion of First Peoples in our study is important to ensure the research is culturally informed, equitable and responsive to community priorities.) based in Victoria and disadvantaged individuals experiencing homelessness. Recruitment methods The recruitment methods are outlined in online supplemental materials 1 and 2 and described in the following paragraphs. We will monitor the recruitment process and participant demographics to ensure an adequate distribution in age, gender and ethnicity in the three cohorts. Participant recruitment via Northern Health: all patients who presented to Northern Health (including VVED and Victorian Virtual Specialist Consults) over the past month (for recruiting cohort 1) or past 24 months (for recruiting cohort 2 and 3) due to COVID-19 infection will be contacted by the authorised researchers via email and/or text message through the Research Electronic Data Capture or telephone calls, if required, to invite participation. Individuals from CALD communities who may require language assistance will be contacted by a bilingual research assistant or an accredited interpreter via a telephone call. People who reply ‘Yes’ to the text message or email or express interest via telephone will be asked to complete a screening survey to assess their eligibility. Participant recruitment via professional networks and the long COVID Facebook group: an email about the study will be sent to clinicians within our professional networks, allowing initial outreach to potentially hundreds of people living with long COVID. An advertisement post for recruitment and a study flyer with a link or QR code to the screening survey will be shared through these networks via mediums such as newsletters, social media platforms and on-site postings. These materials will also be made available on the RMIT intranet and in the long COVID Facebook group. Participant recruitment (including individuals with low SES and those experiencing homelessness) via HoHA: an advertisement flyer and study information will be shared on the HoHA weekly e-newsletter, website, social media channels and/or posted at the HoHA community well-being hub. Potential participants may contact authorised researchers in person. Participant recruitment (First Peoples based in Victoria) via HoHA and site principal investigator’s network: an advertisement flyer containing the contact information of the First Peoples site principal investigator (PI) will be shared on the HoHA website and social media channels or posted at the HoHA community well-being hub. Potential participants may contact the PI via email, telephone or in person. A First Peoples research assistant will assist the PI in recruitment, data collection and entry. Data collection A range of data collection methods will be offered to accommodate participant preferences, including online, telephone and in-person approaches. Special efforts will be made to engage individuals from CALD backgrounds, First Peoples communities and people experiencing homelessness. Bilingual and First Peoples researchers on the team will support recruitment and participation to ensure equitable access and inclusion. Screening and consent Individuals who respond to the study advertisement, email or flyer will be invited to complete an online screening survey to assess their eligibility. Those who are eligible will be automatically directed to the next page, which contains the Participant Information and Consent Form (PICF) to be reviewed online. They will also receive a copy of PICF by email, or post, or in person. Participants will be given a week to read the PICF and consider their participation. At the conclusion of the screening survey, eligible respondents will be informed that a researcher will contact them within 1 week. During this time, they are encouraged to review the PICF and reach out with any questions. A designated researcher will phone potential participants within a week to confirm eligibility, explain the PICF and address any questions or concerns before they decide whether to provide consent to participate in the study. If a participant prefers not to be contacted by phone, all communication may be conducted via email. If they choose to participate, consent may be provided through one of three methods: (1) signing an electronic consent form (e-consent); (2) signing the PICF and emailing it to the study team; (3) signing a mailed PICF and returning it in the prepaid envelope; or (4) signing the PICF in person with a researcher. Once consent is obtained, researchers will collect demographic information during the phone appointment. Alternatively, participants may be provided with a secure online link via email or text message to complete the demographic form if they prefer. Participants will then receive a follow-up email or SMS through REDCap with a participant ID number and a secure web link to access the survey. Those who prefer not, or are unable, to complete the survey online will have the option of completing it via telephone or in person with a researcher, who will enter their responses directly into the online survey. Alternatively, a paper version of the survey will be mailed to them along with a prepaid return envelope. If an individual is unable to complete the survey themselves for any reason, a family member, friend or carer—if they have one—is permitted to complete it on their behalf. For First Peoples participants, the site PI for HoHA, supported by a First Peoples research assistant, will oversee culturally appropriate screening and consent processes. The PICF will be provided via email or in person, with at least 1 week for review. Written or verbal consent will then be obtained during a follow-up appointment. Surveys will typically be completed in person, with the option for online participation if preferred. Where required, participants may receive assistance from friends, family members, or a carer (if they have one) to complete the surveys. Survey responses will be entered by the research assistant into the secure online platform. Baseline and follow-up An overview of the screening process, study groups and survey timeline is shown in figure 1. Screened and eligible participants will be asked to complete a series of surveys assessing the impacts of long COVID at seven time points over a 2-year period: day 1 (baseline), day 7, month 3, month 6, month 12, month 18 and month 24. The day 1 and day 7 surveys differ in content, while subsequent surveys (month 3 onwards) will be similar in structure and content. Flow diagram showing the screening process, study groups and the timeline for administering the study surveys. The first 300 baseline respondents will be included in the psychometric validation analysis. Each survey takes about 30–60 min in total, and participants can complete it at their own pace over a 3-day period. They can save their progress and return to the survey at any time during that window. Participants who report ongoing long COVID symptoms at the end of the 2-year follow-up (month 24) may be invited to participate in an extended follow-up period of an additional 12 months (year 3). During this period, two further surveys will be administered at month 30 and month 36. Data collection points Two authorised members of the research team will independently oversee data collection and monitoring. They will have no personal relationships with the participants and will not be their healthcare providers. Data collection will primarily be conducted online, with the option to complete surveys by telephone or in person. All proposed data collection timepoints are outlined in online supplemental material 3. Data linkage A key purpose of the data linkage is to understand the healthcare resources that have been used by the participants and to calculate the cost associated with the healthcare utilisation. These data will also form part of the assessment of the financial impacts of long COVID. This section outlines the protocol for linking participant survey data with administrative health datasets to objectively measure healthcare utilisation and calculate associated costs. This process will adhere to the highest standards of governance, privacy and data security as mandated by Australian national data linkage authorities. To ensure compliance with best-practice protocols, all data linkage activities will be conducted by accredited government data linkage units. The study will follow a standardised cross-jurisdictional linkage pathway: National data linkage will be facilitated by BioGrid Australia (BioGrid) using the GRHANITE privacy-protecting linkage software. BioGrid is a member-owned data linkage company that works to facilitate collaborative medical research. Participant identifiers (name, date of birth, sex, Medicare number digits 5–9) will be provided to BioGrid, who will create a one-way cryptographic hash including a project-specific person number (PPN). No personal identifiers will be sent to the Australian Institute of Health and Welfare (AIHW). Survey content data with PPN will be securely transferred to AIHW in a separate file. National data linkage will be facilitated by BioGrid Australia (BioGrid) using the GRHANITE privacy-protecting linkage software. BioGrid is a member-owned data linkage company that works to facilitate collaborative medical research. Participant identifiers (name, date of birth, sex, Medicare number digits 5–9) will be provided to BioGrid, who will create a one-way cryptographic hash including a project-specific person number (PPN). No personal identifiers will be sent to the Australian Institute of Health and Welfare (AIHW). Survey content data with PPN will be securely transferred to AIHW in a separate file. AIHW will apply the GRHANITE hashes and link the cohort to the AIHW Enhanced Medicare Spine. The PPN enables linkage to NHDH datasets within the AIHW Secure Access Environment (SAE) without exposing participant identities. AIHW will apply the GRHANITE hashes and link the cohort to the AIHW Enhanced Medicare Spine. The PPN enables linkage to NHDH datasets within the AIHW Secure Access Environment (SAE) without exposing participant identities. We will seek to link data about hospitalisations (emergency department presentations, hospital admissions, intensive care unit admissions via The Australian and New Zealand Intensive Care Society and non-admitted patient (outpatient) visits), Medicare-subsidised medical services (MBS), pharmaceutical dispensing, COVID-19 vaccination records (Australian Immunisation Register [AIR]) and deaths (National Death Index [NDI]). These datasets are held by AIHW who permit approved studies to access data via the National Health Data Hub (NHDH). Approved project data is linked to national datasets within the project’s individual SAE. We will seek to link data about hospitalisations (emergency department presentations, hospital admissions, intensive care unit admissions via The Australian and New Zealand Intensive Care Society and non-admitted patient (outpatient) visits), Medicare-subsidised medical services (MBS), pharmaceutical dispensing, COVID-19 vaccination records (Australian Immunisation Register [AIR]) and deaths (National Death Index [NDI]). These datasets are held by AIHW who permit approved studies to access data via the National Health Data Hub (NHDH). Approved project data is linked to national datasets within the project’s individual SAE. Approvals: ethical approval for the data linkage component of this study has been granted by St Vincent’s Human Research Ethics Committee (HREC). In Australia, approval from the HREC is a prerequisite before applications to linkage agencies and data custodians can be submitted. Following receipt of HREC approval, we submitted the data linkage application on 18 March 2026. No data linkage activities will commence until all required approvals from linkage agencies and data custodians have been formally granted. Approvals: ethical approval for the data linkage component of this study has been granted by St Vincent’s Human Research Ethics Committee (HREC). In Australia, approval from the HREC is a prerequisite before applications to linkage agencies and data custodians can be submitted. Following receipt of HREC approval, we submitted the data linkage application on 18 March 2026. No data linkage activities will commence until all required approvals from linkage agencies and data custodians have been formally granted. Participant privacy will be protected through strict adherence to the following principles: The separation principle: in accordance with national best practice, the linkage process will maintain a strict separation of identifying information (eg, name, address) from health and clinical information. At no point will any single individual have access to both a participant’s identity and their sensitive health data. The separation principle: in accordance with national best practice, the linkage process will maintain a strict separation of identifying information (eg, name, address) from health and clinical information. At no point will any single individual have access to both a participant’s identity and their sensitive health data. Secure data environments: linked data will be accessed only within the project’s NHDH SAE. Individual record-level data cannot be downloaded. All analysis outputs must pass AIHW vetting before release from the SAE. Secure data environments: linked data will be accessed only within the project’s NHDH SAE. Individual record-level data cannot be downloaded. All analysis outputs must pass AIHW vetting before release from the SAE. Confidentiality agreements: all members of the research team who are granted access to the secure environment will be required to sign legally binding deeds of confidentiality and acknowledgement. Confidentiality agreements: all members of the research team who are granted access to the secure environment will be required to sign legally binding deeds of confidentiality and acknowledgement. To ensure the validity of the research findings, a formal assessment of the data linkage quality has been undertaken. The statistical analysis plan will include the calculation and reporting of key linkage quality metrics, including linkage precision and recall. The administrative datasets listed in online supplemental material 4 will be requested for linkage. Initial linkage will occur following AIHW approval, with subsequent extraction cycles at 12-month intervals through to March 2029. Data management All survey data will be collected in REDCap, a secure, web-based application hosted on RMIT’s server. Each participant will be assigned a unique participant ID so that their survey responses are not directly linked to personal identifiers. Email addresses used for survey invitations will be stored in REDCap’s participant list, a separate, access-restricted table visible only to authorised researchers with Manage Survey Participants permissions. The de-identified dataset will be regularly downloaded to the secure, password-protected server at RMIT, and the active REDCap project will be locked or archived by the coordinating PI at the end of the study in accordance with the RMIT data-management policy. Linked NHDH unit-record data will remain in the AIHW NHDH SAE and will be archived or destroyed in accordance with AIHW policies. Identifiable and coded datasets will be stored separately on the password-protected SharePoint site within RMIT’s secure network. Identifiable information (eg, name, date of birth, address, phone number, Medicare number) and the re-identification key will sit in a restricted folder accessible only to authorised researchers involved in recruitment, consent, data collection and data linkage. Permissions will be managed using SharePoint’s Group and Manage Access features. Coded data will be held in a separate SharePoint folder that can be accessed only by team members responsible for data analysis, quality control or governance. No direct identifiers will be stored alongside coded data. Minimal hard copies of data will be maintained and securely stored either at the RMIT West Bundoora Campus in a locked filing cabinet within a restricted-access room, or in a locked filing cabinet in the level 3 research office at Northern Health. These hard copies will be scanned and archived electronically. All electronic data will be securely stored on a password-protected RMIT server. Digital data from Northern Health will be stored in a password-protected folder on a shared drive. Data collected from HoHA will follow the same process as RMIT: digital files will be stored on the RMIT server and physical documents such as PICFs will be securely transferred to RMIT for storage. For data linkage, a multi-layered security approach is employed: Identifier separation: participant identifiers are held by RMIT (survey data) and BioGrid (linkage) only. AIHW receives only GRHANITE hash keys, never participant identifiers. Identifier separation: participant identifiers are held by RMIT (survey data) and BioGrid (linkage) only. AIHW receives only GRHANITE hash keys, never participant identifiers. One-way hashing: the GRHANITE hash is cryptographically one-way and cannot be reversed to reveal identifiers. One-way hashing: the GRHANITE hash is cryptographically one-way and cannot be reversed to reveal identifiers. SAE: linked content data is accessed exclusively within the NHDH SAE, a cloud-based workspace with enterprise security controls. SAE: linked content data is accessed exclusively within the NHDH SAE, a cloud-based workspace with enterprise security controls. No data download: no linked data may be downloaded from SAE to RMIT systems. All analysis must occur within the SAE. No data download: no linked data may be downloaded from SAE to RMIT systems. All analysis must occur within the SAE. Output vetting: all analysis outputs are vetted by AIHW before release from the SAE to ensure no re-identification risk. Output vetting: all analysis outputs are vetted by AIHW before release from the SAE to ensure no re-identification risk. Secure environment: BioGrid maintains the study participant IDs and PPN within a secure environment to enable future re-linkage. Secure environment: BioGrid maintains the study participant IDs and PPN within a secure environment to enable future re-linkage. All survey data will be stored for a minimum of 7 years and disposed of in accordance with RMIT’s data management policy. The linked data will be stored in the NHDH SAE and destroyed at the end of the retention period in accordance with AIHW policies. Data analysis plan Phase 1: user-testing, content validity and pilot testing User-testing: we have collected qualitative attitudinal data, recording both the audio and visuals during a testing session for content analysis purposes. Information regarding participants’ thoughts, beliefs and self-reported needs is obtained to provide feedback on how they describe the characteristics of the survey’s content. First, audio and video data will be transformed into written text (via transcription and captioning), then classified into measure-based sections (ie, risk factors, C19-YRSm, etc), before categories and a coding scheme are determined by the researchers. Next, employing the survey as a framework for deductive coding, each interview will be reviewed and coded to identify and understand themes, patterns and relationships within the data, with the resulting themes reviewed and reported on. In determining the efficiency of completion as well as frequency of errors, user testing enables us to determine the strengths and weaknesses of the tools and methods of resolving issues.36 47 All user testing sessions are undertaken online and recorded via video and screen-capture. Early analysis has consisted of verbal and text summaries to inform discussions with survey developers, LEAN members and community consultants within the iterative development process. Summative analysis will incorporate quantitative analysis and qualitative ethology of user behaviour reflexive thematic analysis of interview responses. This feedback is essential for refining the survey and will be detailed in future publications. Content validity: we conducted one focus group and seven one-on-one interviews with individuals with expertise in either long COVID or cultural competence to assess the survey’s relevance and cultural appropriateness for use in Australia. Transcripts were analysed using a content analysis approach to refine survey items. Pilot testing (cognitive debrief): after completing content validity assessments, a pilot test was conducted with a small sample of Australians (n=10). This test assessed operational aspects, clarity, relevance and ease of use of the instrument. Feedback from the pilot has informed any necessary revisions. The research team examined any proposed revisions to ensure that they constitute adaptation to the Australian long COVID context rather than substantive changes with respect to the original scale. Phase 2: psychometric validation The psychometric properties of C19-YRSm and EQ-5D-5L will be evaluated for the first time for suitability with the Australian population with long COVID. Structural/construct validity: confirmatory factor analysis (CFA) will be used to evaluate the two-dimensional structure of the C19-YRSm scale: Symptom Severity and Functional Disability domains. The factor structure will be evaluated using a number of established metrics, including root mean-square error of approximation; comparative fit index; Tucker-Lewis Index; and standardised root mean squared residual. Factor structure stability will be assessed by invariance testing across time points. Convergent validity: we will evaluate the correlation between (1) C19-YRSm and the FACIT-Fatigue scale, (2) C19-YRSm and MAPS. Pearson’s correlation coefficient will be used for this analysis. Known-groups validity: the C19-YRSm subscales and EQ-5D-5L will be assessed by comparing scores across different patient groups defined by symptom frequency and clinical outcomes. Cross-validity: cross validity of the C19-YRSm and EQ-5D-5L will be evaluated. Invariance testing across groups will be conducted for both recruitment cohorts and specific demographic cohorts with sufficient representation to allow multigroup CFA. Demographic factors will include sex/gender, age and CALD status. Invariance across time points will also be tested. Internal reliability: Cronbach’s alpha will be used to assess the internal consistency of C19-YRSm and EQ-5D-5L. A value above 0.7 is required to confirm adequate internal consistency. Responsiveness and test–retest reliability: the responsiveness of the EQ-5D-5L will be assessed as a comparator for those patients who had completed both the C19-YRSm. Mean change and the intraclass correlation coefficients will be assessed to evaluate the stability and responsiveness. Phase 3: the longitudinal prospective cohort study Multivariable regression models will be used to identify factors predictive of symptom persistence and change. Quantitative data collected from the surveys will be analysed to compare the profiles and the predictive factors of developing long COVID compared with non-long COVID. Analyses will also be conducted at multiple levels to examine variation across subgroups (if sample size allows), taking into account factors such as the stage/severity of long COVID, presence or absence of comorbidity (captured via a structured checklist of pre-existing conditions and included as categorical variables), and personal and situational factors including gender, age and ethnicity. Classification of the severity of long COVID will be based on the C19-YRSm symptom severity score: severe (>20/30), moderate (10–20/30) and mild (<10/30) levels.23 Analyses will be conducted to characterise the symptoms, functional profiles and overall impact of long COVID on individuals. Analyses will include descriptive statistics, repeated measures analysis of variance (ANOVA) across time-points and between groups, ANOVA across demographic cohorts. Changes in symptom severity, function and impacts over time will be assessed using linear mixed modelling, accounting for intra-individual correlations and missing data. SPSS, Mplus or R will be used to analyse the data. As pre-existing conditions are captured using a self-reported checklist without detailed clinical information (eg, severity or timing), findings related to comorbidity should be interpreted with appropriate caution. Discussion This national longitudinal, multi-cohort study aims to (1) characterise the long-term and wide-ranging impacts of long COVID on Australians, (2) develop a set of tools for future clinical and research use and (3) identify factors associated with recovery trajectories. A defining strength of the study is its extensive stakeholder engagement across all stages of development. The survey incorporates internationally validated tools alongside custom questions that were developed and refined based on feedback from people with lived experience, healthcare professionals supporting people with long COVID, health interpreters, statisticians, researchers who led previous long COVID survey studies and First Peoples researchers, all of whom contributed to strengthening the overall design. This embedded qualitative work, combined with a broad stakeholder reach within a quantitative prospective cohort framework, enhances the relevance and implementability of the survey tools for the target population. The quantitative component involves administering the validated tools and custom questions at multiple time points. This longitudinal design enables the identification of distinct recovery trajectories and factors associated with persistent symptoms or functional limitations. While previous surveys have tracked participants for up to 2 years, either prospectively or retrospectively,3810 12 our study commences more than 5 years after the initial SARS-CoV-2 pandemic and will capture the ongoing experiences of people living with long COVID beyond this period. To further enhance the scope, the study includes a subcohort of participants who are 1–3 months post-COVID-19 infection, providing a unique opportunity to examine the early course of the condition and the potential transition from acute infection to long COVID. Tracking this group may offer valuable insights into symptom development, fluctuation or resolution, as well as identifying factors such as changes in diet, physical activity or other behaviours that may be associated with recovery over time.48 At present, the absence of a dedicated diagnostic code for long COVID in Australia limits the ability to track healthcare utilisation and associated costs.49 Through systematic screening prior to enrolment and data linkage, our study is expected to provide objective information on healthcare use and financial burden. This focus was consistently endorsed during LEAN consultations and user-testing sessions, in which participants emphasised the importance of capturing the true financial burden associated with long COVID. Together, the study results may inform the development of evidence-based, person-centred care models and support national health policy and service planning. By identifying key impacts and predictive factors across diverse groups, this research may contribute to more equitable and responsive healthcare delivery. The validated toolkit and longitudinal data will also provide a strong foundation for future research. The qualitative component, which includes user-testing and engagement with people who have lived experience of long COVID, focuses on how participants interpret and interact with the survey tools in practice. User-testing among Australians helps to ensure the tools are clear, relevant and accessible across diverse Australian communities, even when based on internationally validated tools. It also allows us to identify and address any practical barriers to understanding or completing the surveys, supporting inclusivity and feasibility.47 In addition, expert review has been undertaken as part of the survey selection and refinement process to assess the content validity of the selected tools and custom questions. Structured feedback from Australian experts in long COVID and cultural competence ensures that each domain appropriately reflects the intended construct and is suitable for use across Australian populations. Insights from the qualitative phase have guided adjustments to help ensure the surveys are delivered in a way that is responsive to participants’ needs. Together, this integrated study design strengthens the overall rigour, relevance and real-world applicability of the study. A key strength of this study is its use of triangulation to enhance the relevance and rigour of the survey instruments.50 Qualitative data obtained through user-testing, patient engagement and expert review were integrated with quantitative tool development to ensure the surveys are accessible, acceptable and meaningful to people with lived experience of long COVID in Australia. Ongoing patient input has refined the survey content, helping to align the study with the priorities and lived realities of those most affected by long COVID. Additionally, the longitudinal design is expected to enable the study to track changes in symptoms, functioning and broader impacts over time, providing valuable insight into the lived experience and recovery trajectories of long COVID. The selected tools are well-suited to the needs of the Australian population and are informed by prior research. The deliberate inclusion of participants from diverse backgrounds, including CALD communities and First Peoples, enhances the cultural relevance and generalisability of the findings and supports further validation of the tools within these diverse groups. The study is supported by a multidisciplinary team which includes clinicians and medical researchers (infectious diseases, immunology, general practice, emergency medicine), nurses, allied health practitioners and researchers (dietitians, physiotherapists, psychologists, nutrition scientists, mobility, mental health, traditional medicine) together with researchers across health social science, community engagement, economics, education and digital innovation. While grounded in multidisciplinary practice, this study also integrates interdisciplinary perspectives, incorporating lived experience to refine the survey tools—an approach that distinguishes it from other long COVID research. A potential limitation of this study is that while the study design allows for the identification of associations between participant characteristics and outcomes, it does not support causal inference.51 To address this, the study will employ a triangulation approach, apply multiple statistical techniques, and integrate data from different studies to enhance the credibility of potential causal inferences.51 As with many observational studies that rely on voluntary participation, there is also a risk of sampling and selection bias.52 Individuals who choose to enrol may differ systematically from those who do not, which may influence the representativeness of the sample. This will be partly mitigated by including a cohort recruited at least 1 month after a confirmed COVID-19 infection, where invitations are based on a positive test and ongoing symptoms rather than self-identification as having long COVID. Additional potential limitations include participant attrition over time and the potential for missing data, which are common challenges in longitudinal research.53 To improve retention and reduce attrition, participants will receive an initial contact via phone to explain the study and consent process, after which they may select their preferred mode of survey delivery (email, SMS, telephone or in-person administration). Providing flexible survey delivery options is expected to facilitate participation and support ongoing engagement.5456 Missing data will be managed by the multiple imputation approach to reduce bias or increase the precision of the results. We are also refining the survey through an iterative design process to help minimise missing data at the source.53 In addition, we will (1) perform sensitivity analyses to evaluate the impact of missing data on key findings and (2) clearly report the extent and handling of missing data in the final analysis to ensure transparency.53 A further limitation of observational studies is the reliance on self-reported data, which may be subject to recall bias, reporting inaccuracies and variation in interpretation.57 58 To mitigate this, we will seek linkage to national datasets such as MBS and AIR, allowing for the validation of self-reported data and enhancing the overall accuracy and robustness of study findings. Finally, individuals with severe long COVID and those experiencing substantial energy limitation or impairment may be under-represented in our study. Despite the flexible data collection modes implemented, some people may still lack the health capacity or stamina to participate. As observed in related conditions, such as ME/CFS where an estimated 25% of people are bedbound, the most severely affected groups are often the least reachable in research.59 This limitation will be carefully considered when interpreting the generalisability of our findings. Ethics and dissemination Ethical considerations Ethics approval was obtained from The St Vincent’s Hospital Melbourne (SVHM) Human Research Ethics Committee (112108/2024/PID00364) for the survey selection, psychometric-validation and longitudinal survey phases, and RMIT University High-Risk HREC (28124) for the user-testing component. The project is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR; ACTRN12625001415493). This study will be conducted in accordance with the National Statement on Ethical Conduct in Human Research (NHMRC, 2007, updated 2018). All participants will be provided informed consent prior to their participation, and their confidentiality will be maintained throughout the study. Dissemination Research findings with de-identified data are expected to be presented at conferences and in peer-reviewed publications and will be made available to participants on request in the form of a report or summary of results. The findings may also inform policy, clinical guidelines and the development of care models for long COVID. Supplementary material